Literature DB >> 16799708

Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Maher A Sughayer1, Maha M Al-Khawaja, Suleiman Massarweh, Mahmoud Al-Masri.   

Abstract

The management and prognosis of breast cancer nowadays require the evaluation of Estrogen (ER), Progesterone Receptors (PR) and HER2/neu. Ethnic variation in the expression of these receptors is well documented. The aim of this study is to determine the prevalence of ER, PR and HER2/neu among Jordanian women with breast cancer of ductal and lobular types. A retrospective analysis was performed on 267 cases of breast cancer referred for treatment at King Hussein Cancer Center, Jordan between the period of June 2003 and June 2004. Standard immune stains were used for evaluation of hormone receptors and HER2/neu. In addition, evaluation of HER2/neu was done by FISH in selected cases. Of these 267 cases, 240 (89.9%) were ductal carcinomas of various histological grades, 122 (50.8%) of which were ER-positive, 138 (57.5%) PRpositive and 42 (17.5%) HER2/neu-positive. Twentytwo (8.2%) of all cases were lobular carcinomas, 15 (68%) of which were ER-positive, 20 (90.9%) PRpositive and 3 (13.6%) HER2/neu-positive. Five (1.9%) of the total cases were of mixed lobular and ductal types, 4 (80%) of which were ER-positive, 3 (60%) PR-positive and none were positive for HER2/neu. The prevalence of hormone receptor positivity in breast cancer of Jordanian women is lower than that of the western populations and close to other populations such as the Chinese and the minor ethnic groups of Northern America (African Americans).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16799708     DOI: 10.1007/bf02893449

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  27 in total

Review 1.  Estrogen responsiveness and control of normal human breast proliferation.

Authors:  E Anderson; R B Clarke; A Howell
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-01       Impact factor: 2.673

Review 2.  HER-2/neu (c-erb-B2) gene and protein in breast cancer.

Authors:  J S Ross; J A Fletcher
Journal:  Am J Clin Pathol       Date:  1999-07       Impact factor: 2.493

3.  [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].

Authors:  G Abadjian; R Antoun
Journal:  J Med Liban       Date:  1996

4.  Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences.

Authors:  A M Ruder; F Lubin; Y Wax; A Geier; E Alfundary; A Chetrit
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

5.  Hormonal receptor determination of 1,052 Chinese breast cancers.

Authors:  L W Chow; P Ho
Journal:  J Surg Oncol       Date:  2000-11       Impact factor: 3.454

Review 6.  Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

Authors:  S Shak
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

7.  Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer.

Authors:  Margaret-Mary Ameyaw; Mohammed Tayeb; Nadia Thornton; Gbolshan Folayan; Mohammed Tariq; Abeer Mobarek; David A Evans; David Ofori-Adjei; Howard L McLead
Journal:  J Hum Genet       Date:  2002       Impact factor: 3.172

8.  Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors.

Authors:  M Stierer; H Rosen; R Weber; H Hanak; J Spona; H Tüchler
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

9.  Steroid-hormone receptors in breast cancer.

Authors:  J L Wittliff
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

10.  The spectrum of breast diseases in Saudi Arab females: A 26 year pathological survey at Dhahran Health Center.

Authors:  S S Amr; A R Sa'di; F Ilahi; S S Sheikh
Journal:  Ann Saudi Med       Date:  1995-03       Impact factor: 1.526

View more
  6 in total

1.  Correlation of Hormone Receptor Expression with Histologic Parameters in Benign and Malignant Breast Tumors.

Authors:  Deepti Gupta; Veena Gupta; Nisha Marwah; Meenu Gill; Sumiti Gupta; Gopal Gupta; Promil Jain; Rajeev Sen
Journal:  Iran J Pathol       Date:  2015

2.  Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.

Authors:  Stefan Michiels; Richard F Potthoff; Stephen L George
Journal:  Stat Med       Date:  2011-02-23       Impact factor: 2.373

3.  A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data.

Authors:  Majid A Runnak; Mohammed A Hazha; Hassan A Hemin; Abdulmahdi A Wasan; Rashid M Rekawt; Hughson D Michael
Journal:  BMC Womens Health       Date:  2012-06-22       Impact factor: 2.809

4.  Changing Trends in Estrogen Receptors/Progesterone Receptors/Human Epidermal Growth Factor Receptor 2 Prevalence Rates Among Jordanian Patients With Breast Cancer Over the Years.

Authors:  Anas M Alsughayer; Tamara Z Dabbagh; Rashid H Abdel-Razeq; Ghada N Al-Jussani; Salam Alhassoon; Maher A Sughayer
Journal:  JCO Glob Oncol       Date:  2022-03

5.  The cancer translational research informatics platform.

Authors:  Patrick McConnell; Rajesh C Dash; Ram Chilukuri; Ricardo Pietrobon; Kimberly Johnson; Robert Annechiarico; A Jamie Cuticchia
Journal:  BMC Med Inform Decis Mak       Date:  2008-12-24       Impact factor: 2.796

6.  Systematic review of breast cancer biology in developing countries (part 1): Africa, the middle East, eastern europe, Mexico, the Caribbean and South america.

Authors:  Riyaz Bhikoo; Sanket Srinivasa; Tzu-Chieh Yu; David Moss; Andrew G Hill
Journal:  Cancers (Basel)       Date:  2011-05-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.